Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Shopify Inc. (SHOP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Shopify Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Shopify Inc. trades at $118.9 (market cap $158.16B). The key difference: Shopify Inc. is far larger — about 35.2× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Shopify Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | SHOP | |
|---|---|---|
Market Cap | $4.49B | $158.16B |
Sector | Health | Technology |
52-Week High | $28.06 | $179.01 |
52-Week Low | $20.06 | $95.40 |
Enterprise Value | $3.69B | $152.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Shopify (SHOP) trades at $121.88, up 2.03% on the day, with a bullish technical setup showing strong moving average signals and support near $117. Revenue grew to $11.56B in 2025 with a 10.77% net margin, though valuation multiples remain elevated. Recent news highlights Bank of America reinstating a Buy rating with a $150 target, citing AI commerce tools and partnership developments.
Outlook is positive with analyst consensus at $149.10 and 63% Buy ratings, but high P/E of 117.78 poses valuation risk. Key opportunities include AI-driven growth and expanding merchant services, while risks involve competitive pressures and reliance on e-commerce trends. Cash flow trends show improving operations, supporting continued investment in innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →
